I posted on it this morning; this afternoon, Forbes is on it:
It seems Merck may have some ulterior motives, here -- Merck gets all of the profits from Cordaptive (due to be approved by FDA as early as next week), which will likely cannibalize some (more) of the Vytorin/Zetia market-share. . . .
In short, "Why share with Schering-Plough (on Vytorin/Zetia), when we have a new drug -- Cordaptive -- one that goes 100 percent to our own bottom line?"
That seems to be what Merck was wondering, softly, yesterday, and now aloud, to Forbes (off the record, of course).
Tuesday, April 22, 2008
Forbes is on to my story, of this morning, now. . . .
Subscribe to:
Post Comments (Atom)
2 comments:
I'M HEADING UP CLASS-ACTIONS against Merck/S-Plough's Vytorin & Inegy fiasco.
See the latest U.S. House investigation letter:
http://energycommerce.house.gov/Press_110/110-ltr.041108.MerckScheringPlough.pdf
See the Attachments to the letter:
http://energycommerce.house.gov/Press_110/110-ltr.041108.MerckScheringPlough.ENHANCE_Attachments.pdf
Any Questios on Merck/ Schering-Plough Ethics?
ANYONE CARE TO HELP CLEAN OUT/UP KENILWORTH??? Confidential call @ 800-842-8335.
TO ALL READING THE ABOVE ANONYMOUS COMMENT:
~~~~~~~~~~~~~~
I have not endorsed -- or even verified -- the 800 number listed above. If you want to get involved in the class action(s), I'd suggest that you contact one of the attorneys of record on the case files I've linked to in my earlier posts, on this website.
~~~~~~~~~~~~~~~~
Now, Anon. Poster No. 1:
Are you an attorney?
That would be the only way you could "head up" the class actions you mention.
You are aware, of course, that a Lead Plaintiff, and Lead and Coordinating Counsel, have all already been named, in an order signed by Judge Cavanaugh, on april 17, 2008, in MDL Case No. 08-397, the lead case, in the consolidated federal cases, thus far filed, right?
I do appreciate the energy you show here, but it is not a great idea to "cold-call" solicit prospective clients, in this way, in my opinion.
Just the same, Good Luck.
Post a Comment